|Bid||2.05 x 1200|
|Ask||2.06 x 3200|
|Day's Range||2.05 - 2.12|
|52 Week Range||1.29 - 3.09|
|Beta (3Y Monthly)||-0.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.50|
CLEVELAND, Ohio, Oct. 09, 2018 -- Athersys, Inc. (NASDAQ: ATHX) will release its third quarter 2018 financial results at approximately 4:00 p.m. Eastern Time on Tuesday,.
Alnylam Pharmaceuticals (ALNY) submits a Clinical Trial Authorization application in the U.K. to start a phase I/II study on its early stage candidate, ALN-AAT02, for treating alpha-1 liver disease.
Amgen (AMGN) gains an FDA approval for its sNDA with respect to a once-weekly dosing option of its multiple myeloma drug Kyprolis (70 mg/m2) combined with dexamethasone (Kd).
HENDERSON, NV / ACCESSWIRE / October 2, 2018 / The global stem cell market is expected to reach US 270.5 Billion by 2025, while increasing at a compound annual growth rate of 13.8% during the period from ...
CEO invited to provide corporate overview and speak in two workshops focusing on innovative development initiatives in Japan and advanced manufacturing technologies. CLEVELAND, Ohio, Sept. 24, 2018-- Athersys, ...
A look at the shareholders of Athersys Inc (NASDAQ:ATHX) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to seeRead More...
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Williams ...
CLEVELAND, Aug. 07, 2018-- Athersys, Inc. announced today its financial results for the three months ended June 30, 2018.. Highlights of the second quarter of 2018 and recent events include:. Announced ...
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Athersys, Inc. (NASDAQ: ATHX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern Time. To ...
Athersys, Inc. (ATHX) announced the addition of an experienced manufacturing executive to oversee manufacturing operations and help plan for and lead the Company’s transition into commercial manufacturing of MultiStem®, the Company’s patented and proprietary “off-the-shelf” investigational stem cell therapy. Mr. Gregory Liposky, MBA will serve as the Company’s Senior Vice President of Commercial Manufacturing.
Athersys, Inc. (ATHX) announced today that the first patient has been enrolled its Phase 3 study entitled, MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (“MASTERS-2”) to evaluate MultiStem® cell therapy treatment of patients who have suffered an ischemic stroke. The MASTERS-2 clinical trial is a randomized, double-blind, placebo-controlled clinical trial designed to enroll 300 patients in North America and Europe who have suffered moderate to moderate-severe ischemic stroke.
HENDERSON, NV / ACCESSWIRE / July 12, 2018 / The global regenerative medicine market size is expected to reach USD 5.59 billion by 2025, according to a new report by Grand View Research, Inc. With that being said this market could bring incredible value to shareholders of regenerative medicine companies over the next several years. With BioRestorative Therapies, Inc. (BRTX) we noticed that the market cap of this company is so low it could very well have a lot of room to grow.
While the first half did not turn out to be great for the biotech sector, the second half is expected to be much better. Here, we list four biotechs poised for a good run.
On Tuesday, June 12, 2018, the NASDAQ Composite and the S&P 500 edged 0.57% and 0.17% higher, respectively at the closing bell, while the Dow Jones Industrial Average stayed bearish, finishing marginally lower by 0.01%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), Atara Biotherapeutics Inc. (NASDAQ: ATRA), Athersys Inc. (NASDAQ: ATHX), and Auris Medical Holding AG (NASDAQ: EARS).
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Five Below Inc (NASDAQ: FIVE ) stock was trading higher ...
Athersys, Inc. (ATHX) announced today that it has entered into an agreement with HEALIOS K.K. ("Healios") to expand their collaboration into additional therapeutic areas. Under the terms of the agreements, Healios obtained exclusive licenses for the development and commercialization in Japan of MultiStem® therapy for the treatment of acute respiratory distress syndrome ("ARDS") and of MultiStem cells used in combination with iPSC-derived cells for the treatment of certain organs.